Positive selection based on hormone signal transduction
Nippon Paper Industries Co. Ltd holds patents regarding vectors and methods of plant transformation using an auxin biosynthesis gene and/or cytokinin biosynthesis gene as positive selectable markers.
Technology overview
The patent family represented by US 6767735 and EP 1033409 discloses the use of plant hormone signal transduction genes as positive selection markers in a plant transformation vector, which can be excised after selection in order to generate selection marker-free transgenic plants. This method eliminates selection of false-positive plants that have not acquired the gene but show a morphological abnormality phenotype due to the influence of hormone produced by the true transformants close by.
The Japanese patent application JP 2001275667 claims the invention of use of a cytokinin-related gene in plant transformation. Addition of the cytokinin-related gene enhances transformation efficiency, as well as being useful as a positive selection marker gene (that can later be excised using transposons or a site-specific recombination system, or controlled by use of an inducible promoter upstream of the cytokinin-related gene). The application states that the reason for enhanced transformation efficiency is unknown, but relates the effect to cytokinins causing enhanced cell division of the plant.
Another patent family, represented by the United States patent application US 2004/163143, discloses a method of plant transformation using a vector that contains a gene coding for an enzyme that synthesises auxin from an auxin precursor (auxin synthesis gene). By adding the auxin precursor to the selection medium, transformants will synthesise auxin and produce adventitious shoots. The auxin synthesis gene can later be excised using a transposon or site-specific recombination system after selection to regenerate physiologically normal transformants with only the desired gene. Although not claimed in this published application, the applicant suggests the parallel introduction of a cytokinin synthesis gene to control the auxin/cytokinin ratio in the plant. The applicant states that the ‘appropriate’ auxin/cytokinin ratio in transformants (as opposed to non-transformants) will promote shoot generation.
Specific patent information
| Patent/Application Number |
Title, Independent Claims and Summary |
Assignee | |
|---|---|---|---|
|
Title - Vector for introducing a gene into a plant using a selectable marker
|
Nippon Paper Industries Co. Ltd. |
|
|
EP 1033409
|
Title - Vector for introducing a gene into a plant using a selectable marker
The claim is drawn to a vector comprises a desired gene and a plant hormone signal transduction gene for selection. A method for producing a transgenic plant cell is also claimed in the independent claim 10, which comprises the transformation of plant cells with the vector and the selection of transformed cells in the presence of plant hormones. |
||
|
Remarks |
Related patent applications were also filed in Canada (CA 2292798) and Japan (JP 2001218583). |
||
|
JP 2001275667
|
Title - Method of enhancing gene-transferring efficiency for monocotyledon
|
||
|
Remarks |
There is no family information for this Japanese patent application according to INPADOC. |
||
|
Title - Method for efficiently producing transgenic plant using auxin precursor
Definitions from the specification: "Auxin" is a plant hormone and is known to accelerate elongation, proliferation and division of cells. "Auxin precursor and/or an analogue" is a substance which is converted into auxin or a substance having a physiological activity similar to that of auxin (hereinafter also referred to as "auxin-like substance" as a whole) by the expression of the auxin precursor-auxin synthesis gene introduced as a selectable marker gene. |
||
|
Remarks |
Related patent applications were also filed in Japan (JP 2004057066), Australia (AU 2003221268 A1), Europe (EP 1384785 A1), Canada (CA 2436046 A1 ) and China (CN 1473936 A). |
The information contained in this page was believed to be correct at the time it was collated. New patents and patent applications, altered status of patents, and case law may have resulted in changes in the landscape. CAMBIA makes no warranty that it is correct or up to date at this time and accepts no liability for any use that might be made of it. Corrections or updates to the information are welcome. Please send an email to info@bios.net.



There are no comments.